Mild Cognitive Impairment and Neurofeedback: A Randomized Controlled Trial

Area of Science:

• Neuroscience
• Cognitive Science
• Gerontology

Background:

• Mild cognitive impairment (MCI) often precedes dementia, particularly Alzheimer's Disease (AD).
• Individuals with amnestic MCI have a significantly higher risk of developing AD.
• MCI represents an early, detectable stage for therapeutic intervention and prevention strategies.

Purpose of the Study:

• To investigate the efficacy of electroencephalography (EEG)-based neurofeedback in enhancing memory performance in patients with MCI.
• To explore the potential of neurofeedback in reversing common EEG alterations observed in MCI patients.
• To address memory decline, a primary symptom and predictor of cognitive deterioration in MCI and AD.

Main Methods:

• Utilized EEG-based neurofeedback to improve memory performance in MCI patients.
• Implemented a protocol to enhance upper alpha band activity through positive feedback.
• Compared an experimental group receiving targeted neurofeedback with a sham group receiving random feedback.

Main Results:

• Significant memory performance improvement observed in the experimental neurofeedback group compared to the sham group.
• Memory enhancement in the experimental group was sustained for at least one month post-intervention.
• EEG-based neurofeedback demonstrated a positive impact on memory function in MCI subjects.

Conclusions:

• EEG neurofeedback presents a promising, affordable, and novel therapeutic approach for MCI.
• This method may help mitigate memory decline associated with mild cognitive impairment.
• Neurofeedback could be a valuable tool in managing early-stage cognitive deterioration and potentially delaying AD progression.